FREDERICK, Md., April 20 /PRNewswire-FirstCall/ -- Computer Sciences Corporation announced today that DynPort Vaccine Company LLC (DVC), a joint venture between CSC and Porton International Inc., has demonstrated the efficacy of its recombinant plague vaccine. In initial testing, DVC's plague vaccine protected mice against both the bubonic and pneumonic forms of plague, a critical step in the development of a plague vaccine for human use.
This testing evaluated the efficacy of DVC's recombinant F1V (rF1V) plague vaccine candidate in mice. The material used in these studies was manufactured by ID Biomedical Corporation (IDBE:Nasdaq, IDB:TSX), headquartered in Vancouver, British Columbia. The mice were immunized at an ID Biomedical research facility in Montreal, Quebec. The immunized mice were then challenged with both forms of plague (Yersinia pestis) at the U. S. Army Medical Research Institute for Infectious Diseases (USAMRIID) in Fort Detrick, Md. The study, which began in December 2003 and ended in late February 2004, showed good correlation between the antibody response of the mice and their survival rates.
"DVC is rapidly advancing this recombinant plague vaccine to human clinical trials," said DVC president Terry Irgens. "The goal is to produce a vaccine that protects people from the plague, which is contagious and extremely lethal."
DVC's plague vaccine is based on work conducted at USAMRIID.
DVC is a biopharmaceutical company dedicated to the development and licensure of safe and efficacious biodefense vaccines for the Department of Defense, through the Joint Vaccine Acquisition Program, and civilian populations.
DVC is part of CSC's Enforcement, Security and Intelligence (ESI) organization, which CSC created in 2002 to support programs enhancing U.S. security.
Porton International Inc. is a wholly owned subsidiary of the Ipsen Group, a European mid-sized specialist pharmaceutical company.
Founded in 1959, Computer Sciences Corporation is a leading global information technology (IT) services companies. CSC's mission is to provide customers in industry and government with solutions crafted to meet their specific challenges and enable them to profit from the advanced use of technology.
With approximately 90,000 employees, CSC provides innovative solutions for customers around the world by applying leading technologies and CSC's own advanced capabilities. These include systems design and integration; IT and business process outsourcing; applications software development; Web and application hosting; and management consulting. Headquartered in El Segundo, Calif., CSC reported revenue of $13.8 billion for the 12 months ended Jan. 2, 2004. For more information, visit the company's Web site at http://www.csc.com/.
The safety and efficacy of this product in humans has not been established. The product is currently under clinical investigation and has not been approved by the FDA.
All statements and assumptions in this press release that do not directly and exclusively relate to historical facts constitute "forward-looking statements" within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements represent the current expectations and beliefs of Computer Sciences Corporation, but are subject to risks, uncertainties and other factors that could cause actual results to differ materially from the results described in such statements. For a description of these factors, see the section titled "Management's Discussion and Analysis of Financial Condition and Results of Operations; Forward-Looking Statements" in CSC's Annual Report on Form 10-K for the fiscal year ended March 28, 2003.
Contact: April Finnen
DVC Public Relations
ID Biomedical Corporation